A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

• Status: Not yet recruiting
• Trial end date: 2021-06-08
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the effect of inhibitors, at steady state, on the drug levels, safety, and tolerability of BMS-986235 when taken by healthy participants. The inhibitors to be utilized in this study are fluconazole, bupropion, and itraconazole.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Bupropion; Fluconazole; Itraconazole

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Body mass index of 18.0 kg/m2 to 32.0 kg/m2, inclusive, at screening.

• Males and females must agree to follow specific methods of contraception, if applicable.

• Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations, and no significant findings in medical history.

Exclusion Criteria:

• Women of childbearing potential (WOCBP), women who are pregnant or breastfeeding

• Inability to tolerate oral medication

• Known previous exposure to BMS-986235.

Other protocol-defined inclusion/exclusion criteria apply